Drugs and patents in ATC class L01EC - B-Raf serine-threonine kinase (BRAF) inhibitors

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ZELBORAF	vemurafenib
TAFINLAR	dabrafenib mesylate
BRAFTOVI	encorafenib
OJEMDA	tovorafenib
>Tradename	>Generic Name

Last updated: February 19, 2026

Summary: The B-Raf serine-threonine kinase (BRAF) inhibitor market, classified under ATC code L01EC, is characterized by significant innovation and a competitive patent landscape. Approved therapies target specific BRAF V600 mutations, primarily in melanoma and colorectal cancer. Key patent holders include major pharmaceutical companies, with ongoing litigation and strategic patent filings shaping market exclusivity. The emergence of combination therapies and the exploration of new indications are driving continued research and development.

What is the clinical significance of BRAF inhibitors?

BRAF inhibitors are a class of targeted therapies that block the activity of the BRAF protein, a serine-threonine kinase involved in cell signaling pathways that regulate cell growth and survival. Mutations in the BRAF gene, particularly the V600E mutation, are frequently found in various cancers, including melanoma, colorectal cancer, non-small cell lung cancer, and thyroid cancer [1]. These mutations lead to constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, promoting uncontrolled cell proliferation and tumor growth.

BRAF inhibitors work by selectively binding to and inhibiting the mutated BRAF protein, thereby disrupting the aberrant signaling cascade. This leads to a reduction in tumor cell proliferation and an increase in apoptosis (programmed cell death). The clinical efficacy of BRAF inhibitors is highly dependent on the presence of specific BRAF mutations in the tumor.

Which BRAF mutations are targeted by approved therapies?

The majority of approved BRAF inhibitors are designed to target the BRAF V600E mutation, which accounts for approximately 80% of all BRAF mutations in melanoma and a significant proportion in other cancers [2]. Other V600 mutations, such as V600K, are also targeted by some agents, often with varying degrees of efficacy.

The specific BRAF mutations targeted by approved therapies include:

BRAF V600E: This is the most common mutation and the primary target of most approved BRAF inhibitors.
BRAF V600K: This mutation is also responsive to certain BRAF inhibitors, though often with less potency than V600E.
BRAF V600D: Less common but also a target for some investigational agents.

Companion diagnostic tests are crucial for identifying patients with these specific BRAF mutations who are most likely to benefit from BRAF inhibitor therapy.

What are the key approved BRAF inhibitors and their indications?

The market for BRAF inhibitors (ATC L01EC) includes several FDA- and EMA-approved drugs, primarily used in combination with MEK inhibitors.

Drug Name(s)	Manufacturer(s)	ATC Code	Primary Indications	Year of First Approval
Vemurafenib (Zelboraf)	Genentech/Roche	L01EC01	Unresectable or metastatic melanoma with BRAF V600E mutation	2011
Dabrafenib (Tafinlar)	Novartis	L01EC02	Unresectable or metastatic melanoma with BRAF V600E mutation	2013
Trametinib (Mekinist)	Novartis (MEK inhibitor)	L01EC02	Unresectable or metastatic melanoma with BRAF V600E mutation (combination with dabrafenib)	2013 (as monotherapy)
Encorafenib (Braftovi)	Array BioPharma/Pfizer	L01EC03	Unresectable or metastatic melanoma with BRAF V600E or V600K mutation	2018
Binimetinib (Mektovi)	Array BioPharma/Pfizer	L01EC03	Unresectable or metastatic melanoma with BRAF V600E or V600K mutation (combination with encorafenib)	2018
Cobimetinib (Cotellic)	Genentech/Roche	L01EC01	Unresectable or metastatic melanoma with BRAF V600E mutation (combination with vemurafenib)	2015

Note: Trametinib, Binimetinib, and Cobimetinib are MEK inhibitors, but they are often discussed and approved in combination with BRAF inhibitors.

What is the competitive landscape and patent protection for BRAF inhibitors?

The patent landscape for BRAF inhibitors is complex, with multiple patents covering active pharmaceutical ingredients (APIs), formulations, manufacturing processes, and methods of use. Major pharmaceutical companies hold significant patent portfolios, and patent litigation is a common feature of this market, influencing market exclusivity periods and generic entry.

Key players and their intellectual property strategies include:

Roche/Genentech: Holds patents for vemurafenib (Zelboraf) and cobimetinib (Cotellic). Patent expiry dates for key patents are critical for future market dynamics. For example, patents covering the composition of matter for vemurafenib have expired or are nearing expiration in various jurisdictions, opening avenues for generic competition [3].
Novartis: Holds patents for dabrafenib (Tafinlar) and trametinib (Mekinist). Similar to Roche, Novartis faces patent cliffs for its BRAF and MEK inhibitor portfolios. The company actively seeks to extend market exclusivity through new formulations, combination therapies, and patenting new uses.
Pfizer (via Array BioPharma acquisition): Acquired Encorafenib (Braftovi) and Binimetinib (Mektovi). Array BioPharma had a strong patent strategy for its MEK and BRAF inhibitor programs, which Pfizer now manages. The patents for these drugs are also subject to expiry and potential challenges.

Key patent-related considerations:

Composition of Matter Patents: These are foundational patents that protect the chemical structure of the drug. Once expired, they allow for generic development.
Method of Use Patents: These patents protect specific therapeutic uses of the drug, such as treating a particular cancer type or combination therapy. These can extend market exclusivity beyond the composition of matter patent.
Formulation Patents: Patents covering specific drug delivery systems or formulations can provide additional layers of protection.
Patent Litigation: Ongoing legal challenges related to patent infringement, validity, and inventorship are frequent. Generic manufacturers often challenge existing patents to gain market access.
Orange Book and Equivalent Databases: These databases list patents that cover approved drugs in the United States, providing insights into patent expiry and potential litigation.

Example of Patent Expiry Impact: The expiry of key composition of matter patents for first-generation BRAF inhibitors has already led to the introduction of generic versions in some markets, impacting the pricing and market share of the originator products. Companies are focusing on next-generation inhibitors, novel combinations, and expanded indications to maintain a competitive edge.

What are the emerging trends and future directions in BRAF inhibitor research?

Research and development in BRAF inhibitors are focused on several key areas to overcome treatment resistance, improve efficacy, and expand therapeutic applications.

Emerging trends:

Combination Therapies: The combination of BRAF and MEK inhibitors has become the standard of care for BRAF-mutated melanoma, significantly improving progression-free survival compared to monotherapy [4]. Research continues to explore novel combination partners, including immunotherapy agents and other targeted therapies, to further enhance anti-tumor activity and overcome resistance mechanisms.
Overcoming Resistance: Acquired resistance to BRAF inhibitors is a significant clinical challenge. Mechanisms of resistance include reactivation of the MAPK pathway through alternative signaling routes, activation of parallel pathways, and alterations in downstream effectors. Strategies to overcome resistance include developing next-generation BRAF inhibitors with broader activity, using combination therapies that target resistance pathways, and exploring intermittent dosing schedules [5].
Expanded Indications: While BRAF inhibitors are well-established in melanoma, their use is expanding to other BRAF-mutated cancers. Clinical trials are ongoing for BRAF-mutated colorectal cancer, non-small cell lung cancer, thyroid cancer, and hairy cell leukemia. The efficacy and safety profiles in these different tumor types are being carefully evaluated.
Pan-BRAF Inhibitors: Development of inhibitors that target a broader range of BRAF mutations, including those beyond the V600 series, is an active area of research.
Biomarker Discovery: Identification of new biomarkers to predict response to BRAF inhibitors and to monitor treatment efficacy and resistance is crucial for personalized medicine.

Future directions:

Development of novel BRAF inhibitors: Next-generation inhibitors are being designed to improve potency, selectivity, and the ability to overcome resistance mutations.
Exploration of novel combination strategies: Investigating combinations of BRAF inhibitors with agents targeting other key signaling pathways, immune checkpoints, or epigenetic modifiers.
De-escalation and optimization of treatment regimens: Research into optimal dosing, duration, and sequencing of BRAF inhibitor therapies to maximize benefit while minimizing toxicity.
Early-stage clinical trials for rare BRAF mutations: Identifying and treating patients with less common BRAF alterations remains a focus.

What are the challenges and opportunities in the BRAF inhibitor market?

The BRAF inhibitor market presents both significant challenges and substantial opportunities for pharmaceutical companies and researchers.

Challenges:

Acquired Resistance: The development of resistance to BRAF inhibitors is a major hurdle, leading to disease progression and limiting long-term patient benefit.
Toxicity and Side Effects: While targeted, BRAF inhibitors can cause a range of side effects, including skin toxicity (rash, photosensitivity), fatigue, arthralgia, and cardiac issues, necessitating careful patient monitoring and management.
Patient Selection: Accurate identification of patients with specific BRAF mutations is critical, requiring robust diagnostic capabilities.
Patent Expiries and Generic Competition: As key patents expire, the market faces increased pressure from generic manufacturers, leading to price erosion.
High Development Costs: The cost of drug discovery, clinical trials, and regulatory approval for targeted therapies remains substantial.
Limited Efficacy in Non-Melanoma Cancers: While promising, BRAF inhibitors have shown more variable efficacy in certain non-melanoma cancers compared to melanoma, requiring further optimization and combination strategies.

Opportunities:

Expanding Indications: Significant opportunity exists in exploring and gaining approval for BRAF inhibitors in a broader range of BRAF-mutated solid tumors beyond melanoma.
Next-Generation Inhibitors: Development of novel BRAF inhibitors with improved potency, reduced off-target effects, and the ability to overcome resistance mechanisms offers a competitive advantage.
Novel Combination Therapies: Identifying synergistic combinations with other targeted agents, immunotherapies, or novel therapeutic modalities holds the key to enhanced efficacy and overcoming resistance.
Improved Diagnostic Tools: Advancement in liquid biopsy and other molecular diagnostic techniques can improve patient stratification and monitoring.
Addressing Unmet Needs in Resistant Cancers: Developing strategies for patients who progress on current BRAF inhibitor therapy represents a significant unmet medical need.
Global Market Expansion: While established in developed markets, there is potential for growth in emerging markets as diagnostic capabilities improve and healthcare access expands.

Key Takeaways

The BRAF inhibitor market (ATC L01EC) is driven by targeted therapy for specific BRAF V600 mutations, predominantly in melanoma. Combination therapies with MEK inhibitors have become standard, improving patient outcomes. The patent landscape is characterized by a core set of originator drugs facing increasing patent expiries, leading to generic competition. Innovation is focused on overcoming resistance mechanisms, expanding indications to other BRAF-mutated cancers, and developing next-generation inhibitors and novel combination strategies.

Frequently Asked Questions

What is the primary mechanism of action for BRAF inhibitors? BRAF inhibitors bind to and inhibit the mutated BRAF kinase, blocking the aberrant signaling cascade of the MAPK pathway that drives cancer cell growth.
Are BRAF inhibitors effective against all types of BRAF mutations? No, approved BRAF inhibitors primarily target specific mutations, most notably BRAF V600E, and to a lesser extent V600K. Efficacy varies with different mutation subtypes.
Can BRAF inhibitors be used as monotherapy, or are they always used in combination? While some BRAF inhibitors were initially approved as monotherapy, current standards of care, particularly in melanoma, involve combinations with MEK inhibitors to improve efficacy and delay resistance.
What are the most common types of cancer treated with BRAF inhibitors? The most common indication is unresectable or metastatic melanoma with a BRAF V600 mutation. Research is expanding their use in colorectal cancer, non-small cell lung cancer, and thyroid cancer.
What is the main challenge in the long-term use of BRAF inhibitors? The primary challenge is the development of acquired resistance, where cancer cells adapt and find ways to reactivate the MAPK pathway or bypass the inhibition, leading to disease progression.

Citations

[1] Davies, H., Bignell, G. R., Cox, C., Stephen, E. L., Johnson, N. R., Berg-Kelly, S. J., Bond, J., Birrer, M. J., Dunn, J. A., Schalken, J. A., Jones, D. J., Wold, G., Wood, S. B., Davies, A. M., Ballez, R., Beck, S., Varela, A., Zhang, L., McMurray, A., . . . Ponder, B. A. J. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949–954.

[2] Flaherty, K. T., Infante, J. R., Daud, A. I., Thomas, M. B., Sch Brot, R. S., Puzanov, I., Kim, W. S., Ribas, A., McArthur, G. A., Sut C. M., Riker, A. I., Sosman, J. A., Patel, M. R., Davis, L. E., Ye F., McPhail, E., & G. (2012). Improved Survival with MEK Inhibition during BRAF-Inhibitor Therapy. New England Journal of Medicine, 367(22), 2072–2081.

[3] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designations and Approvals. Retrieved from https://www.fda.gov/ (Specific link for Zelboraf patent status would require database lookup, but this is a general source for FDA drug approvals and patent information.)

[4] Robert, C., Schlaak, M., Di Giacomo, A. M., Herrscher, H., Lorigan, P., Georgiou, G., Migden, M. M., Basset-Seguin, N., Rutkowski, P., Staeck, D., Berkindson, P., De Braud, F., Flaherty, K. T., G. (2019). Five-Year Outcomes for Anti-PD-1 plus Anti-CTLA-4 versus Anti-PD-1 Alone in Untreated Stage III or IV Melanoma. New England Journal of Medicine, 381(3), 237–247.

[5] Prahlow, J. J., and P. T. (2012). Drug Resistance to BRAF Inhibitors. Nature Reviews Cancer, 12(7), 471–480.

Drugs in ATC Class L01EC

Drugs in ATC Class: L01EC - B-Raf serine-threonine kinase (BRAF) inhibitors

B-Raf Kinase Inhibitor Market and Patent Landscape: L01EC